Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (GB:0VAU)
LSE:0VAU
RESEARCH TOOLSreports
Holding GB:0VAU?
Track your performance easily
0VAU Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Oncolytics Biotech News
PremiumCompany Announcements
Oncolytics Biotech’s Promising Breast Cancer Study
PremiumCompany Announcements
Oncolytics Biotech Engages Investors at Key Conferences
PremiumCompany Announcements
Oncolytics Biotech Announces Equity Distribution DealBulls Say, Bears Say
Bulls Say
Clinical TrialsOncolytics is planning to launch a Phase 2 study with the intent of seeking accelerated approval in HR+/HER2- metastatic breast cancer, following positive feedback from FDA post-Type C meeting.
CollaborationsEntered into collaboration with GCAR for inclusion of pelareorep in an adaptive registration-enabling pancreatic cancer trial in combination with Tecentriq.
Financial PositionThe company expects its current cash position of $24.9M to provide cash runway through 2025 to support the trials being run for pelareorep across various indications, including breast, pancreatic, and anal cancers.
Bears Say
Capital OverhangCapital overhang is expected to maintain pressure on the stock as cash runway is estimated into early 2025, close to breast cancer data.
Clinical Development RiskClinical development risk tied to pelareorep in multiple tumor types poses a significant threat to the stock's performance.
Competitor And Market RisksCompetitor risk in relevant therapeutic areas and capital market and dilution risk could negatively impact the stock's value.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.56%
Insiders
0.05% Mutual Funds
0.58% Other Institutional Investors
96.80% Public Companies and
Individual Investors
0VAU FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Currently, no data Available
What is Oncolytics Biotech’s market cap?
Currently, no data Available
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Nov 13, 2024 which is in 48 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Aug 01, 2024. The company reported -C$0.1 earnings per share for the quarter, beating the consensus estimate of -C$0.102 by C$0.002.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -C$0.1.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 76,986,030 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -C$0.1 in its last earnings report, beating expectations of -C$0.102. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in GB:0VAU
---
Oncolytics Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$6.45 (― Upside)
C$6.45 (― Upside)
Blogger Sentiment
Bearish
GB:0VAU Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.79%
12-Months-Change
Fundamentals
Return on Equity
-137.23%
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
---
0VAU Earnings Call
Q2 2024
0:00 / 0:00
---
0VAU Stock 12 Month Forecast
Average Price Target
―Oncolytics Biotech
―
Advaxis
―
Moleculin Biotech
―
TRACON Pharmaceuticals
―
Cyclacel Pharmaceuticals
―
Best Analysts Covering 0VAU
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-12.48%
reiterated a buy rating 8 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -12.48% per trade.
---